Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

Autres documents

SML2561

Sigma-Aldrich

ML162

≥98% (HPLC)

Synonyme(s) :

α-[(2-Chloroacetyl)(3-chloro-4-methoxyphenyl)amino]-N-(2-phenylethyl)-2-thiopheneacetamide, 2-Chloro-N-(3-chloro-4-methoxyphenyl)-N-(2-oxo-2-(phenethylamino)-1-(thiophen-2-yl)ethyl)acetamide, BRD-5421, BRD5421, CID 3689413, ML 162, ML-162, Molecular Libraries 162

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H22Cl2N2O3S
Numéro CAS:
1035072-16-2
Poids moléculaire :
477.40
Numéro MDL:
MFCD03450805
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white to very dark brown

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

2-8°C

Actions biochimiques/physiologiques

ML162 is a small molecule that induces ferroptosis via covalent inhibition of cellular phospholipid glutathione peroxidase (GPX-4; GPX4; GSHPx-4; PHGPx; snGPx; snPHGPx). Synthetic lethality studies in cancer cultures identify contributing factors such as HRas(G12V) expression and fumarate hydratase (FH) deletion to ML162 sensitivity (IC50 = 25 nM & 35 nM, respectively, in BJeLR-HRas(G12V) & UOK262-FH-/- cultures).

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Michel Weïwer et al.
Bioorganic & medicinal chemistry letters, 22(4), 1822-1826 (2012-02-03)
Synthetic lethal screening is a chemical biology approach to identify small molecules that selectively kill oncogene-expressing cell lines with the goal of identifying pathways that provide specific targets against cancer cells. We performed a high-throughput screen of 303,282 compounds from
Emilie Logie et al.
International journal of molecular sciences, 22(22) (2021-11-28)
Disease relapse and therapy resistance remain key challenges in treating multiple myeloma. Underlying (epi-)mutational events can promote myelomagenesis and contribute to multi-drug and apoptosis resistance. Therefore, compounds inducing ferroptosis, a form of iron and lipid peroxidation-regulated cell death, are appealing
Amrita Basu et al.
Cell, 154(5), 1151-1161 (2013-09-03)
The high rate of clinical response to protein-kinase-targeting drugs matched to cancer patients with specific genomic alterations has prompted efforts to use cancer cell line (CCL) profiling to identify additional biomarkers of small-molecule sensitivities. We have quantitatively measured the sensitivity
Vasanthi S Viswanathan et al.
Nature, 547(7664), 453-457 (2017-07-06)
Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple
Kenichi Shimada et al.
Cell chemical biology, 23(2), 225-235 (2016-02-09)
Precision medicine in oncology requires not only identification of cancer-associated mutations but also effective drugs for each cancer genotype, which is still a largely unsolved problem. One approach for the latter challenge has been large-scale testing of small molecules in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique